Bioventus chose Bazis NN as its authorized distributor for DUROLANE® single-injection joint-fluid osteoarthritis (OA) treatment in Russia.
“We believe the OA market in Russia is underserved and the patients there will benefit greatly from DUROLANE,” said John Nosenzo, Chief Commercial Officer, Bioventus. “Bazis has a terrific track record in marketing and selling orthopaedic solutions in Russia and we are pleased they are helping Bioventus reach more patients and physicians with our proven pain reliever for osteoarthritis.”
Bioventus chose Bazis NN as its authorized distributor for DUROLANE® single-injection joint-fluid osteoarthritis (OA) treatment in Russia.
“We believe the OA market in Russia is underserved and the patients there will benefit greatly from DUROLANE,” said John Nosenzo, Chief Commercial Officer, Bioventus. “Bazis has a terrific track record...
Bioventus chose Bazis NN as its authorized distributor for DUROLANE® single-injection joint-fluid osteoarthritis (OA) treatment in Russia.
“We believe the OA market in Russia is underserved and the patients there will benefit greatly from DUROLANE,” said John Nosenzo, Chief Commercial Officer, Bioventus. “Bazis has a terrific track record in marketing and selling orthopaedic solutions in Russia and we are pleased they are helping Bioventus reach more patients and physicians with our proven pain reliever for osteoarthritis.”
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
